HK1071567A1 - Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity - Google Patents

Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity

Info

Publication number
HK1071567A1
HK1071567A1 HK05104387A HK05104387A HK1071567A1 HK 1071567 A1 HK1071567 A1 HK 1071567A1 HK 05104387 A HK05104387 A HK 05104387A HK 05104387 A HK05104387 A HK 05104387A HK 1071567 A1 HK1071567 A1 HK 1071567A1
Authority
HK
Hong Kong
Prior art keywords
spirosubstituted
thetreatment
piperidines
obesity
receptor antagonists
Prior art date
Application number
HK05104387A
Other languages
English (en)
Inventor
Duane A Burnett
Wen-Lina Wu
Thavalakulam K Sasikumar
Martin S Domalski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1071567A1 publication Critical patent/HK1071567A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK05104387A 2002-06-27 2005-05-25 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity HK1071567A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27
PCT/US2003/020088 WO2004002987A1 (en) 2002-06-27 2003-06-26 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Publications (1)

Publication Number Publication Date
HK1071567A1 true HK1071567A1 (en) 2005-07-22

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104387A HK1071567A1 (en) 2002-06-27 2005-05-25 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity

Country Status (15)

Country Link
US (1) US7109207B2 (ru)
EP (1) EP1532147B1 (ru)
JP (1) JP4522853B2 (ru)
CN (1) CN100374440C (ru)
AR (1) AR040344A1 (ru)
AT (1) ATE334983T1 (ru)
AU (1) AU2003258957A1 (ru)
CA (1) CA2490531C (ru)
DE (1) DE60307289T2 (ru)
ES (1) ES2266861T3 (ru)
HK (1) HK1071567A1 (ru)
MX (1) MXPA05000185A (ru)
PE (1) PE20040749A1 (ru)
TW (1) TW200401777A (ru)
WO (1) WO2004002987A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519876A (ja) 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
CA2515717A1 (en) 2003-02-10 2004-08-19 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
CN1777596A (zh) * 2003-02-28 2006-05-24 先灵公司 作为选择性mch受体拮抗剂用于治疗肥胖及相关病症的联芳基四氢异喹啉哌啶
MXPA06011265A (es) 2004-03-29 2006-12-15 Pfizer Compuestos propanamida alfa aril o heteroaril metil beta piperidino como antagonistas del receptor orl1.
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
JPWO2006104136A1 (ja) * 2005-03-29 2008-09-11 萬有製薬株式会社 非アルコール性脂肪性肝疾患の治療剤、及び非アルコール性脂肪性肝疾患の治療又は予防のための薬剤の候補化合物のスクリーニング方法
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
AU2007301126A1 (en) * 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
WO2011146069A1 (en) 2010-05-21 2011-11-24 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
US10407428B2 (en) * 2014-11-21 2019-09-10 Esteve Pharmaceuticals, S.A. Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
AU769081B2 (en) 1999-08-26 2004-01-15 Bristol-Myers Squibb Company NPY antagonists: spiroisoquinolinone derivatives
EP1268000A4 (en) * 2000-03-23 2004-12-29 Merck & Co Inc SPIROPIPERID DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE

Also Published As

Publication number Publication date
CN1665812A (zh) 2005-09-07
JP2005535641A (ja) 2005-11-24
ATE334983T1 (de) 2006-08-15
DE60307289T2 (de) 2007-10-18
US20040024002A1 (en) 2004-02-05
AR040344A1 (es) 2005-03-30
US7109207B2 (en) 2006-09-19
EP1532147A1 (en) 2005-05-25
PE20040749A1 (es) 2004-10-23
TW200401777A (en) 2004-02-01
ES2266861T3 (es) 2007-03-01
CN100374440C (zh) 2008-03-12
EP1532147B1 (en) 2006-08-02
CA2490531A1 (en) 2004-01-08
DE60307289D1 (de) 2006-09-14
AU2003258957A1 (en) 2004-01-19
JP4522853B2 (ja) 2010-08-11
WO2004002987A1 (en) 2004-01-08
MXPA05000185A (es) 2005-04-08
CA2490531C (en) 2011-03-22

Similar Documents

Publication Publication Date Title
HK1071567A1 (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity
AU2003243497A8 (en) Antagonists of melanin concentrating hormone receptor
EP1653960A4 (en) MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST
HK1047580B (zh) 在糖尿病治療中作為糖皮質激素受體對抗劑的二苯並吡喃
IL190898A0 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
AU2003287880A8 (en) Cyclic quinoline compounds for use in mch receptor related disorders
EP1444251A4 (en) CYCLIC PEPTIDES AS G PROTEIN-COUPLED RECEPTOR ANTAGONISTS
IL166344A0 (en) Device for tectile stimulation
HK1107261A1 (en) Method of wound healing using a2b adenosine receptor antagonists
EP1536813A4 (en) COMPOSITIONS AND METHODS FOR PROTEIN-ACTIVATED RECEPTOR ANTAGONISTS
AU2003267088A8 (en) Chemokine receptor antagonists as therapeutic agents
AU2003300904A8 (en) Antagonists for human prolactin
AU2003280675A1 (en) SELECTIVE HUMAN Beta3 ADRENALIN RECEPTOR AGONIST AGENT
IL180098A0 (en) Methods for predicting therapeutic pesponse to agents acting on the growth hormone receptor
HK1082796A1 (zh) 人p2y15g蛋白偶聯受體的調控
IL180107A0 (en) Lactam tachykinin receptor antagonists
HK1085926A1 (en) Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis
AU2003297124A8 (en) F11 receptor(f11r) antagonists as therapeutic agents
AU2003250685A8 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists
AU2003242848A8 (en) Nuclear hormone receptor ligano-binding domain containing protein
TW535558U (en) Improved structure of device for clamping toilet device
AU2003244831A8 (en) Human nuclear hormone receptor
TW532128U (en) Improved structure of placement frame for bathtub
SI1594520T1 (sl) Uporaba antagonistov bradikinin-B2 receptorja za zdravljenje osteoartroze

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF 20050722: [54] SPIROSUBSTITUTED PIPERIDINES AS SELECTIVEMELANIN CONCENTRATING - HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100626